Back to Search
Start Over
Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company's antibody-cleaving enzyme technology platform
- Source :
- Obesity, Fitness & Wellness Week. August 6, 2022, 36
- Publication Year :
- 2022
-
Abstract
- 2022 AUG 6 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Hansa Biopharma AB, (Hansa), (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology [...]
Details
- Language :
- English
- ISSN :
- 15316386
- Database :
- Gale General OneFile
- Journal :
- Obesity, Fitness & Wellness Week
- Publication Type :
- Periodical
- Accession number :
- edsgcl.712102459